0001213900-21-030103.txt : 20210601 0001213900-21-030103.hdr.sgml : 20210601 20210601073417 ACCESSION NUMBER: 0001213900-21-030103 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210526 FILED AS OF DATE: 20210601 DATE AS OF CHANGE: 20210601 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP CENTRAL INDEX KEY: 0001810117 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31392 FILM NUMBER: 21983021 BUSINESS ADDRESS: STREET 1: BOODENHIMER 24 CITY: TEL AVIV STATE: L3 ZIP: 6200838 BUSINESS PHONE: 00972546444183 MAIL ADDRESS: STREET 1: BOODENHIMER 24 CITY: TEL AVIV STATE: L3 ZIP: 6200838 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PLURISTEM THERAPEUTICS INC CENTRAL INDEX KEY: 0001158780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 980351734 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 BUSINESS PHONE: 972-74-710-7171 MAIL ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 FORMER COMPANY: FORMER CONFORMED NAME: PLURISTEM LIFE SYSTEMS INC DATE OF NAME CHANGE: 20030701 FORMER COMPANY: FORMER CONFORMED NAME: AI SOFTWARE INC DATE OF NAME CHANGE: 20010906 4 1 ownership.xml X0306 4 2021-05-26 1 0001158780 PLURISTEM THERAPEUTICS INC PSTI 0001810117 CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 24 BODENHIMER STREET TEL AVIV, L3 6200838 ISRAEL 0 0 1 0 Common Stock 2021-05-26 4 S 0 122663 3.68 D 3354825 D Common Stock 2021-05-26 4 S 0 22015 3.69 D 3332810 D Common stock 2021-05-27 4 S 0 71775 3.69 D 3261035 D Common stock 2021-05-27 4 S 0 24110 3.69 D 3236925 D Common stock 2021-05-28 4 S 0 70007 3.72 D 3166918 D Common stock 2021-05-28 4 S 0 45000 3.72 D 3121918 D The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.64 to $3.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.63 to $3.73 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.66 to $3.72 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.68 to $3.69 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.72 to $3.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.70 to $3.74 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Clover Wolf Capital - Limited Partnership By: Clover Wolf Ltd., its General Partner /s/ Adi Wolf, Chief Executive Officer and Managing Member 2021-06-01